Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides for Graves Disease: Research vs Clinical Comparison

Thymalin T-regulatory cell enhancement, thymic hormone restoration Animal models show increased CD4+CD25+ Treg populations (Immunology Letters, 2009) May modulate upstream immune dysregulation driving TRAb production No human trials measuring TRAb suppression

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Thymalin
  • T-regulatory cell enhancement, thymic hormone restoration
  • Animal models show increased CD4+CD25+ Treg populations (Immunology Letters, 2009)
  • May modulate upstream immune dysregulation driving TRAb production
  • No human trials measuring TRAb suppression or TSH normalization
  • Best evidence for immune modulation. But not a replacement for methimazole
  • BPC-157
  • VEGF upregulation, cytokine suppression (TNF-α, IL-6)
  • Reduced systemic inflammation in animal models (J Physiol Pharmacol, 2011)
  • Could reduce tissue damage from chronic hyperthyroid state
  • No thyroid-specific trials; mechanism is indirect
  • Supportive for inflammation. Not for antibody suppression
  • KPV
  • NF-κB inhibition, inflammatory gene suppression
  • Reduced IL-1β and TNF-α in colitis models (Peptides, 2008)
  • Potential for Graves ophthalmopathy (orbital inflammation)
  • Extrapolated from non-thyroid conditions
  • Plausible for ophthalmopathy. Evidence is speculative
  • MK-677
  • GH secretagogue, IGF-1 elevation, anabolic signaling
  • Increased lean mass 1.1kg in 12-week trial (JCEM, 1998)
  • Post-treatment muscle recovery after hyperthyroid wasting
  • Contraindicated during active hyperthyroidism (may worsen tachycardia)
  • Use only after thyroid hormones normalize
  • CJC-1295/Ipamorelin
  • Pulsatile GH release, mTOR pathway activation
  • Preserved lean mass during caloric deficit (Growth Horm IGF Res, 2004)
  • Same as MK-677. Rebuilding lost muscle post-treatment
  • Same contraindication during active disease
  • Effective for recovery. Not for active Graves